Efficacy of berberine in patients with type 2 diabetes mellitus
Efficacy of berberine in patients with type 2 diabetes mellitus
复制标题
DOI：
10.1016/j.metabol.2008.01.013
复制
发表时间：
2008-05-01
影响因子：
9.8
通讯作者：
Ye, Hanping
中科院分区：
文献类型：
--
作者：
Yin, Jun;Xing, Hulli;Ye, Hanping
小檗碱已被证明在体外和体内调节葡萄糖和脂质代谢。本研究旨在探讨黄连素治疗2型糖尿病的有效性和安全性。在研究A中，36名新诊断的2型糖尿病成人患者被随机分配到黄连素或二甲双胍（0.5 g，每日3次）治疗组，为期3个月。小檗碱的降血糖作用与二甲双胍相似。血红蛋白A（1c）显著降低（从9.5% +/- 0.5%到7.5% +/-0.4%，P <0.01），空腹血糖（从10.6 +/- 0.9 mmol/L至6.9 +/- 0.5 mmol/L，P <0.01），餐后血糖（从19.8 +/- 1.7至11.1 +/- 0.9 mmol/L，P
Berberine has been shown to regulate glucose and lipid metabolism in vitro and in vivo. This pilot study was to determine the efficacy and safety of berberine in the treatment of type 2 diabetes mellitus patients. In study A, 36 adults with newly diagnosed type 2 diabetes mellitus were randomly assigned to treatment with berberine or metformin (0.5 g 3 times a day) in a 3-month trial. The hypoglycemic effect of berberine was similar to that of metformin. Significant decreases in hemoglobin A(1c) (from 9.5% +/- 0.5% to 7.5% +/- 0.4%, P < .01), fasting blood glucose (from 10.6 +/- 0.9 mmol/L to 6.9 +/- 0.5 mmol/L, P < .01), postprandial blood glucose (from 19.8 +/- 1.7 to 11.1 +/- 0.9 mmol/L, P